Carrada BT

Language: Spanish
References: 107
Page: 107-125
PDF size: 1760.85 Kb.

ABSTRACT

Despite the epidemic re-emergence of tuberculosis in the late second millennium, we still have another chance to eradicate this disease. Currently available interventions will reduce tuberculosis cases and deaths if they are correctly implemented, but eradication of the disease and latent infections will require more investment in research to develop new drugs, vaccines and diagnostic tests. Public health infrastructure must be improved in the next decades to ensure progress toward this goal. Local health centers must provide all the elements for a comprehensive tuberculosis control program including education and training of health care teams, case identification, surveillance and laboratory monitoring, and direct and strict supervision of treatment. Clinicians will require to be prepared for cases of active disease using updated laboratory methods to establish a prompt diagnosis, identify drug-resistant strains and follow guidelines for prevention and treatment. This work is aimed to review the issues that physicians must know and do as part of the national effort to eradicate tuberculosis in Mexico.

REFERENCES

1. Quirzo-Huerta G, Yánez-Velasco L, Kato-Maeda M, Jaimes-Escobedo ML, Avena-Peralta MA, Santos-Preciado I. TAES. Tratamiento acortado estrictamente supervisado para controlar la tuberculosis. Enf Infect Microbiol 1998;18:83-84.

2. Small PM, Fujiwara PI. Management of tuberculosis in the United States. N Engl J Med 2001;345:189-200.

3. Due C, Scheele S, Dolin P, Pathania V, Raviglione MC. Consensus statement global burden of tuberculosis estimated incidence, prevalence and mortality by country. WHO global surveillance and monitoring project. JAMA 1999;282:677-686.

4. Van Cleeff MR, Chum HJ. The proportion of tuberculosis cases in Tanzania attributable to human inmunodeficiency virus. Int J Epidemiol 1995;24:637-642.

5. De Cock KM, Binkin NJ, Zuber PL, Tappero JW, Castro KG. Research issues involving HIV-associated tuberculosis in resource poor-countries. JAMA 1996;276: 1502-1507.

6. García-García ML, Valdespino-Gómez JL, García-Sancho MC, Salcedo-Alvarez RA. Epidemiología de la tuberculosis y del VIH/SIDA. Temas de medicina interna de la Asociación de Medicina Interna de México 1995;3:809-819.

7. García-García ML, Mayar-Maya ME, Ferreyra-Reyes L, Palacios-Martínez M, Alvarez-García C, Valdespino-Gómez JL. Eficacia y eficiencia del tratamiento antituberculoso en jurisdicciones sanitarias de Morelos, México. Salud Pública Mex 1998;40:421-429.

8. Manjárrez-Morales EM, Serrano-Montes V, Cano-Pérez G, Verduzco-Guerrero E, Escandón-Romero C, Escobedo-de la Peña J. Principales causas de abandono de tratamiento contra la tuberculosis pulmonar. Gac Méd Méx 1993; 129:57-61.

9. Alvarez-Gordillo GC, Halperin-Frisch D, Blancarte-Melendez L, Vázquez-Castellanos JL. Factores de riesgo para resistencia a drogas antifímicas en Chiapas, México. Salud Pública Méx 1995 37:408-416.

10. Laniado-Laborín R, Cabrales-Vargas N. Tratamiento acortado estrictamente supervisado, estrategia necesaria pero no suficiente para controlar la tuberculosis en Baja California, México. Elevadas tasas de multidrogorresistencia en el estado. Rev Inst Nal Enf Resp Méx 2000: 13;23-27.

11. Sifuentes-Osornio J, Ponce de León LA, Camacho-Mezquita E, Bobadilla-del Valle M, Infante-Suárez M. Resistencia de Mycobacterium tuberculosis en pacientes mexicanos. Características clínicas y factores de riesgo. Rev Invest Clin (Méx) 1995; 47:273-281.

12. Olvera-Castillo R, Pérez-González LE. Resistencia secundaria en tuberculosis. Rev Inst Nal Enf Resp 1993;6:185-190.

13. Secretaría de Salud. Mortalidad en México, 1999. Salud Pública Méx 2002;43: 72-73.

14. Celis-Salazar A, Nava S. Patología de la pobreza. Rev Med Hosp Gral (Méx) 1964;33:371-378.

15. Casas-García S. Perfil sociocultural del paciente tuberculoso. Rev Med IMSS (Méx) 1996;34:229-232.

16. Núnez-Rocha GM, Salinas-Martínez AM, Villareal-Rios E, Garza-Elizondo E, González-Rodríguez F. Riesgo nutricional en pacientes con tuberculosis pulmonar: ¿Cuestión del paciente o de los servicios de salud? Salud Pública Méx 2000;42:126-132.

17. Bustamante-Montes LP, Bellido-Bárcenas F, Riojas-Rodríguez H, Borja-Aburto VH, Yañez-Velasco L, Becerra-Posadas F. Características sociodemográficas de personas que murieron por tuberculosis pulmonar en Veracruz, México en 1993. Salud Pública Méx 1996 38:323-331.

18. Spence DPS, Hotchkiss J, Williams CSD, Davies PDO. Tuberculosis y pobreza. BMJ (latinoamericana) 1993;1:365-367.

19. Secretaría de Salud. Manual de Procedimientos del Programa Nacional de Prevención y Control de la Tuberculosis, México: Dirección General de Medicina Preventiva, SSA. 1996.

20. United States. Centers for Disease Control and Prevention. Population –based survey for drug- resistance of tuberculosis, México 1997. MMWR 1998;47:371-375.

21. Tapia R, Ruíz C, Ferreira E. Epidemiología de la tuberculosis en México. En: Sada E, Sifuentes J, editores. Tuberculosis. Mc Graw-Hill/Interamericana: México DF, 1995: 761-788.

22. Garza-Elizondo ME, Salinas-Martínez AM, Núñez-Rocha GM, Villareal-Rios E. Tuberculosis pulmonar. Dominio cultural sobre el origen y evolución de la enfermedad. Rev Med IMSS (Méx) 2001;19:501-507.

23. Piessens WF, Nardell EA. The pathogenesis of tuberculosis. In: Reichman LB, Hershfield ES, editors. Tuberculosis: a comprehensive international approach. 2ª ed. Rev. Nueva York: Marcel-Dekker, 2000:241-260.

24. Small PM, Shafer RW, Hopewell PC. Exogenous reinfection with multidrug-resistant Mycobacterium tuberculosis in patients with advanced HIV infection. N Engl J Med 1993;328:1137-1144.

25. Van Rie A, Warren R, Richardson M. Exogenous reinfection as a cause of recurrent tuberculosis after curative treatment. N Engl J Med 1999;341:1174-1179.

26. Godfrey-Faussett P, Sonnenberg P, Shearer SC. Tuberculosis control and molecular epidemiology in a South African gold-mining community. Lancet 2000;356: 1066-1071.

27. American Thoracic Society. Diagnostic standars and classification of tuberculosis in adults and children. Am J Respir Crit Care Med 2000;161:1376-1395.

28. Hopewell PC. Impact of human immunodeficiency virus infection on the epidemiology clinical featuring, management and control of tuberculosis. Clin Infect Dis 1992;15:540-547.

29. Lugo-Pérez E, Viramontes-Madrid JL, Cicero-Sabido R, Chay-Esquivel LE, Peña-Valencia MH. Tuberculosis pulmonar. Problema hospitalario vigente. Rev Inst Nal Enf Resp Méx 1994;7:131-136.

30. Jones BE, Young SMM, Antoniskis D, Davidson PT, Kramer F, Barnes PF. Relationship of the manifestations of tuberculosis to CD 4 cell counts in patients with human immunodeficiency virus infection. Am Rev Respir Dis 1993;148:1292-1297.

31. Moore M, McCray E, Onorato IM. TB-AIDS versus non-AIDS TB cases, United States 1993-1997 (abstract). Int J Tuberc Lung Dis 1999; 20S.

32. Tuberculosis in relation to human immunodeficiency syndrome. In: Iseman MD, editor. A clinician’s guide to tuberculosis. Filadelfia: Lippincott Williams & Wilkins, 2000;199-252.

33. Molina-Gamboa JD, Ponce de León S, Sifuentes-Osornio J, Bobadilla-del Valle M, Ruíz-Palacios GM. Mycobacterium infectium infection in mexican AIDS patients. J Acqir Immune Def Syndr Hum Retrovir 1995;11:53-58.

34. Aguado GA. Tratamiento de la tuberculosis. Laboratorio y clínica. Madrid: Garsi, 1986:115-133.

35. Fox W, Ellard GA, Mitchison DA. Studios on the treatment of tuberculosis undertaken by the British Medical Research Council tuberculosis unit, 1946-1986, with relevant subsequent publications. Int J Tuberc Lung Dis 1999; 3 Suppl 2: 231S- 279S.

36. Bass JB Jr, Farer LS, Hopewell PC. Treatment of tuberculosis and tuberculosis infection in adults and children. Am J Respir Crit Care Med 1994;149:1359-1374.

37. Centers for Disease Control. Prevention and Treatment of tuberculosis among patients infected with human immunodeficiency virus: principles of therapy and revised recommendations. MMWR Morb Mortal Wkly Rep 1998;47 (RR-20):1-58.

38. Vernon A, Burman W, Benator D, Khan A, Bozeman I. Acquired rifamycin monoresistance in patients with HIV-related tuberculosis treated with one weekly rifapentine and isoniazid. Lancet 1999;53:1843-1847.

39. Chaulk CP, Kazandjian VA. Directly observed therapy for treatment completion of pulmonary tuberculosis: consensus statement of the Public Health Tuberculosis Guidelines Panel. JAMA 1998;279:943-948.

40. Vernon A. TB treatment study 22 (rifapentine trial): preliminary results in VIH-negative patients (abstract). Am J Respir Crit Care Med 2000; 161 Suppl A 252.

41. Barnes PF, Chan LS, Wong SF. The course of fever during treatment of pulmonary tuberculosis. Tubercle 1987; 68:255-260.

42. Medical Research Council. Controlled trial of 6-moths and 9-months regimen of daily and intermittent streptomycin plus isoniazid plus pyrazinamide for pulmonary tuberculosis in Hong-Kong the results up to 30 moths. Am Rev Respir Dis 1977;115: 727-735.

43. Bass JB, editor. Tuberculosis. Clínica Médica Norteamérica. México: Interamericana Mc Graw-Hill, 1993;6:1277-1472.

44. Fujiwara PI, Simone PM, Munsiff SS. The treatment of tuberculosis. In: Reichman LB, Hershfield ES, editors. Tuberculosis: a comprehensive international approach. 2a ed. Nueva York: Marcel-Dekker, 2000: 401-446.

45. American Thoracic Society and Centers for Disease Control and Prevention. Targeted tuberculin testing and treatment of latent tuberculosis infection. Am J Respir Crit Care Med 2000; 161 Suppl 5:221S- 247S.

46. Center for Disease Control. Core curriculum in tuberculosis: what the clinician should know. 4th ed. Atlanta: Centers for Disease Control and Prevention, 2000:2-320.

47. Ostrosky-Zeichner L, Rangel-Fraustro S, García-Romero E, Vázquez A, Ibarra MJ, Ponce de León-Rosales S. Tuberculosis en trabajadores de la salud: importancia de los programas de vigilancia y control. Salud Pública Méx 2000; 42:48-52.

48. Alvarez-Gordillo GC, Dorantes-Jiménez JE, Halperin-Frisch CD. Problemas para el control de la tuberculosis pulmonar en el estado de Chiapas, México. Rev Inst Nal Enf Resp Méx 1998;11:280-287.

49. Kumate J, Gutiérrez G, Muñoz O, Santos-Preciado JI. Tuberculosis e infección por micobacterias atípicas. En: Manual de infectología clínica. 16a ed. México DF: Méndez, 2001:121-136.

50. Pérez-Stable EJ, Flaberry D, Schecter G, Slutkin G, Hopewell PC. Conversion and reversion of tuberculin reactions in nursing home residents. Am Rev Respir Dis 1988;137:801-804.

51. Sutherland I. The ten-year incidence of clinical tuberculosis following “conversion” in 2550 individuals aged 14-19 years. TSRU progress report. La Haya, Países Bajos: KNCV, 1968.

52. Centers for Disease Control and Prevention. Screening for tuberculosis and tuberculosis infection in high-risk population: recommendations of the Advisory Committe for Elimination of Tuberculosis. MMWR Morb Mortal Wkly Rep 1990;39 (RR 8): 1-7.

53. Menzies RJ. Tuberculin skin-testing. In: Reichman LB, Hershfield ES, editors. Tuberculosis: a comprehensive international approach. 2a ed rev. Nueva York: Marcel-Dekker, 2000: 279-322.

54. Ferebee SH. Controlled chemoprophylaxis trials in tuberculosis. A general review. Bibl Tuberc 1970;26:28-106.

55. Unión Internacional contra la Tuberculosis. Comité de Profilaxis. Efficacy of various durations of isoniacid prevention therapy for tuberculosis five year follow-up in the IUAT-trial. Bull World Health Organ 1982;60:555-564.

56. Comstock GW. How much isoniacid is needed for prevention of tuberculosis among immuno-competent adults? Int J Tuberc Lung Dis 1999;3:847-850.

57. Bucher HC, Griffith LE, Guyatt GH. Isoniazid prophylaxis for tuberculosis in HIV infection: a meta-analysis of randomized controlled trials. AIDS 1999;13:501-507.

58. Whalen CC, Johnson JL, Okwera A. A trial of three regimens to prevent tuberculosis in Ugandan adults infected with the human immunodeficiency virus. N Engl J Med 1997; 337:801-808.

59. Halsey NA, Coberly JS, Desormeaux J. Randomized trial of isoniacid versus rifampicin and pyrazinamide for prevention of tuberculosis in HIV-infection. Lancet 1998;351:786-792.

60. Snider DE Jr, Caras GJ, Koplan JP. Preventive therapy with isoniacid: cost-effectiveness of different durations of therapy. JAMA 1986;255:1579-1583.

61. Mwinga A, Hosp M, Godfrey-Faussett P. Twice weekly tuberculosis preventive therapy in HIV infection in Zambia. AIDS 1998;12:2447-257.

62. Gordin FM, Marts JP, Miller C. A controlled trial of isoniazid in persons with anergy and human immunodeficiency virus infection who are at high risk for tuberculosis. N Engl J Med 1997;337:315-320.

63. Gordin F, Chaisson RE, Martz JP. Rifampicin and pyrazinamide vs isoniazid for prevention of tuberculosis in HIV-infected persons: an international randomized trial. JAMA 2000;283:1445-1450.

64. Centers for Disease Control and Prevention. Fatal and severe hepatitis associated with rifampicin and pyrazinamide for the trearment of latent tuberculosis infection. New York and Georgia, 2000. MMWR Morb Mortal Wkly Rep 2001;50:286-291.

65. British Medical Research Council. Hong Kong Chest Service/Tuberculosis Research Centre, Madras. A double-blind placebo-controlled clinical trial of three antituberculosis regimens in patients with silicosis in Hong-Kong. Am Rev Respir Dis 1992;145:36-41.

66. Centers for Disease Control and Prevention. Management of persons exposed to multidrug resistant tuberculosis. MMWR Morb Mortal Wkly Rep 1992; 41(RR-II):61-71.

67. Secretaría de Salud. Norma Oficial Mexicana. NOM-006-SSA 2- para la prevención y control de la tuberculosis en la atención primaria de la salud. Diario Oficial (Méx), jueves 26 de enero de 1995: 1-12.

68. Pacheco RC, Vázquez-Rinza V, Badillo N. Vacuna del bacilo de Calmette y Guerin (BCG). En: Escobar-Gutiérrez A, Valdespino-Gómez JL, Sepulveda-Amor J, editores. Vacunas, ciencia y salud. México: Secretaría de Salud, 1992:187-201.

69. Rojas-Espinoza O. Desarrollo de inmunógenos y vacunas contra lepra y tuberculosis. En: Cabrera-Contreras R, Gómez de León P, Cravioto A, editores. Vacunas. Fundamentos para su desarrollo. México: Manual Moderno, 1996:249-260.

70. Torres M, Herrera TM, Villareal H, Sada-Díaz E. Inducción de citocinas por antígenos de Mycobacterium tuberculosis en infección humana. En: Cabrera-Contreras R, Gómez de León P, Cravioto A, editores. Vacunas. Fundamentos para su desarrollo. México: Manual Moderno, 1996:261-274.

71. Hatfull G, Jacobs WR Jr. Molecular genetics of mycobacteria. Washington DC: ASM Press, 2000.

72. Pelicia V, Reyrat JM, Gicquel B. Genetic advances for studying Mycobacterium tuberculosis pathogenicity. Mol Microbiology 1998;28:413-420.

73. Mc Kinny JD, Honer Zu, Bentrup K, Muñoz-Elias EJ. Persistence of Mycobacterium tuberculosis in macrophages and mice requires the glyoxylate shunt enzyme isocitrate-lyasa. Nature 2000; 406:735-738.

74. Camacho LR, Ensergueix D, Pérez E, Gicquel B, Guihot C. Identification of a virulence gene cluster of Mycobacterium tuberculosis by signature-tagged transposon mutagenesis. Mol Microbiol 1999;34:257-267.

75. Wilson M, De Risi J, Kristensen HH. Exploring drug-induced alterations in gene expression in Mycobacterium tuberculosis by microarray-hibridization. Proc Natl Acad Sci USA 1999;96:1283-1288.

76. Bellamy R, Beyers N, Mc Adam KP. Genetic susceptibility to tuberculosis in Africans: a genome wide scan. Proc Nat Acad Sci USA 2000;97:8005-8009.

77. Ginsberg AM. A proposed national strategy for tuberculosis vaccine development. Clin Infect Dis 2000;30: Suppl 3: 233S-242S.

78. Ellner JJ, Hirsch CS, Whalen CC. Correlates of protective immunity to Mycobacterium tuberculosis in humans. Clin Infect Dis 2000;30:Suppl 3:279S-282S.

79. Jasmer RM, Hahn JA, Smal PM. A molecular epidemiologic analysis of tuberculosis trends in San Francisco, 1991-1997. Ann Intern Med 1999;130:971-978.

80. Pottumarthy S, Morris AJ, Harrison AC, Wells VC. Evaluation of the tuberculin gamma-interferon assay: potential to replace the Mantoux skin test. J Clin Microbiol 1999;37:3229-3232.

81. Behr MA, Wilson MA, Gill WP. Comparative genomics of BCG vaccine by whole-genoma DNA microarray. Science 1999;284:1520-1523.

82. Jungblut PR, Schaible UE, Mollenkup HJ. Comparative proteome analysis of Mycobacterium tuberculosis and Mycobacterium BCG strains: toward functional genomics of microbial pathogens. Mol Microbiol 1999;33:1103-1117.

83. Andersen P, Munk ME, Pollock JM, Doherty TM. Specific immune-based diagnostics of tuberculosis. Lancet 2000;356:1099-1104.

84. Riska PF, Jacobs WR Jr, Alland D. Molecular determinants of drug resistance in tuberculosis. Int J Tuberc Lung Dis 2000; 4: 4S-10S.

85. Temple ME, Nahata MC. Rifapentine: its role in the treatment of tuberculosis. Ann Pharmacother 1999; 33:1203-1210.

86. Holland SM. Cytoquine therapy of Mycobacterial infection. Adv Intern Med 2000; 45:431-452.

87. Small PM, Perkins MD. More rigour needed in trials of new diagnostic agents for tuberculosis. Lancet 2000;356:1048-1049.

88. Blancarte ML, De Jaime ACB, Spíndola S. Importancia de la resistencia a los medicamentos. Trabajo presentado en el XXXII reunión del Grupo Coordinador Internacional de Control de Tuberculosis. México, junio 17, 1993.

89. Vaca-Marín MA, Tlacahuac-Cholula C, Olvera-Castillo R. Tuberculosis pulmonar entre sintomáticos detectados en las unidades de salud de la SSA, en el estado de Tlaxcala. México. Rev Inst Enf Resp Méx 1999;12:29-34.

90. Hopewell PC. Global tuberculosis control: an optimist’s perspective. Int J Tuberc Lung Dis 1999;3:270-272.

91. Netto EM, Dye C, Raviglione MC. Progress in global tuberculosis control with emphasis on 22 high-incidence countries. Int J Tuberc Lung Dis 1999;3:1-14.

92. Murray CJL, Styblo K, Rouillon A. Tuberculosis. In: Jameson DT, editor. Disease control priorities in developing countries. Oxford: Oxford University Press, 1993:16-38.

93. Díaz-Dueñas P, Contreras-Mendoza EJ, Ceja-Espíritu G. Algunas consideraciones sobre la tuberculosis pulmonar. Salud Comunitaria IMSS, 1999;3: 26-28.

94. Centers for Disease Control. Essential components of tuberculosis prevention and control program: recomendations of the advisory council for the elimination of tuberculosis. MMWR. Morb. Mortal Wkly Rep 1995; 44 (RR-II):1-16.

95. Vidal-Pla R, March-Ayuela P. Tratamiento de la infección y enfermedad tuberculosa. Monografías clínicas en neumología. Barcelona: Doyma,1992.

96. Farga V. Tuberculosis. 2a ed. Santiago de Chile: Mediterráneo, 1992.

97. Farmer P, Yong-Kim J. Community based approaches to the control of multidrug-resistant tuberculosis. Introducing “Dot plus”. BMJ 1998;317:671-674.

98. Blowers SM, Small PM, Hopewell PC. Control strategies for tuberculosis epidemics: New Models for old problems. Science 1996; 273:497-500.

99. Laniado-Laborin R, Enriquez-Rosales M, Licea-Navarro AF. Diagnóstico de tuberculosis mediante detección de M. tuberculosis empleando un sistema no comercial de reacción en cadena de polimerasa. Rev Inst Nal Enf Resp Méx 2001; 14:22-26.

100. Peter CR, Schultz E, Mozer K, Cox M, Freeman R, Ramírez-Zetina M, et al. Drugresistant pulmonary tuberculosis in the Baja California-San Diego Country border population. West J Med 1998;169:208-213.

101. Barnes PF. Rapid diagnostic test for tuberculosis. Progress, but not gold standard. Am J Respir Crit Care Med 1997;155:1497-1498.

102. Balandrano-Campos S, Anzaldo-Flores G, Peña-Flores GP. Betancourt-Murillo X. Manual de procedimientos de laboratorio INDRE/SAGAR: tuberculosis, de la Secretaría de Salud, Secretaría de Agricultura, Ganadería y Desarrollo Rural. Washington DC: Organización Panamericana de la Salud, 1996.

103. Villarreal H, Martínez L, Salazar MA, Pérez G, Urrueta J, Olvera R. El control de la tuberculosis en la República Mexicana. Neumol Cir Tórax 1995;54:13-20.

104. Donabedian A. La calidad de la atención médica. Definición y métodos de evaluación. México, DF: La Prensa Médica Mexicana, 1991:3-194.

105. Cosío-Villegas I, Celis-Salazar A. La tuberculosis pulmonar. En: Cosío-Villegas I, Celis-Salazar A, Cosio-Pascal M, editores. Aparato respiratorio. 10ª ed. México: Méndez-Oteo, 1982:507-684.

106. Pérez-Padilla R. La tuberculosis en México, deuda añeja de salud pública. Gac Méd Méx 2001;137:93-94.

107. Granich RM, Balandrano S, Santaella AJ, Binkin NJ, Castro KG, Márquez-Fiol A, et al. Survey of drug-resistance of Mycobacterium tuberculosis in 3 mexican states, 1997. Arch Intern Med 2000;160:639-644.